Latest Headlines

  1. Entered A Partnership With ELITech In The Field Of Molecular Testing For Infectious Disease 9/25/2025

    Hitachi High-Tech Corporation ("Hitachi High-Tech"), and ELITechGroup S.p.A. (Head Office: Italy, "ELITech") have entered a Collaboration, Manufacturing and Supply Agreement (the "Agreement") in the field of molecular testing for infectious disease.

  2. New Research Reinforces C2N's PrecivityAD2 Blood Test As A Highly Accurate Tool To Detect Brain Amyloid Pathology In Symptomatic Patients 9/25/2025

    C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation, is highlighting a peer-reviewed study that independently validates the performance of the PrecivityAD2 blood test among individuals with mild cognitive impairment or dementia.

  3. LigoLab And PathPresenter Announce Strategic Partnership To Deliver Seamless Digital Pathology Workflows 9/25/2025

    LigoLab, a leading provider of enterprise laboratory information system (LIS) software and fully integrated laboratory revenue cycle management (lab RCM) solutions, and PathPresenter, a global leader in digital pathology image viewing and management solutions, today announced a strategic partnership.

  4. Multiple South West London Pathology Trusts Select Indica Labs And Leica Biosystems For Advancing Digital Pathology In Clinical Practice 9/24/2025

    Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announce today that multiple trusts within the South West London Pathology network have chosen the powerful combination of Leica Biosystems Aperio GT 450 DX scanners and Indica Labs’ HALO A for digital pathology adoption.

     

  5. Guardant Health And Quest Diagnostics Announce Strategic Collaboration To Broaden Access To Guardant's Shield Blood-Based Screening Test In The United States 9/24/2025

    Guardant Health, Inc. a leading precision oncology company, and Quest Diagnostics a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield blood-based screening test available to physicians and patients served by Quest in the United States.

  6. Proscia To Expand Pathology AI Capabilities With Virtual Staining 9/24/2025

    Proscia®, a pathology AI company, is introducing virtual staining in its Concentriq® software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows.

  7. Lunit, CellCarta Announce Global Alliance To Expand Access To Digital Pathology AI For Clinical Trials 9/24/2025

    Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development.

  8. PathAI Launches Industry-Backed AIM-HI UC Model On GCP-Compliant Platform To Standardize Histological Assessment In Ulcerative Colitis Trials 9/23/2025

    PathAI, the global leader in AI-powered pathology, today announced the integration of AIM-HI UC1, an advanced AI model for Ulcerative Colitis (UC) histology endpoint assessment, on to AISight Clinical Trials, PathAI’s GCP and GCLP-compliant platform.

  9. Quest Diagnostics To Improve Laboratory Testing Experience With Industry-First Epic Collaboration 9/23/2025

    Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.

  10. Myriad Genetics And SOPHiA GENETICS To Develop An Innovative Companion Diagnostic Offering In Liquid Biopsy 9/23/2025

    Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.